Assessing Roivant Sciences: Insights From 5 Financial Analysts

Across the recent three months, 5 analysts have shared their insights on Roivant Sciences ROIV, expressing a variety of opinions spanning from bullish to bearish.

The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.

In the assessment of 12-month price targets, analysts unveil insights for Roivant Sciences, presenting an average target of $14.8, a high estimate of $17.00, and a low estimate of $12.00. Marking an increase of 0.89%, the current average surpasses the previous average price target of $14.67.

Deciphering Analyst Ratings: An In-Depth Analysis

A clear picture of Roivant Sciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Roivant Sciences. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Roivant Sciences compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Roivant Sciences's stock. This comparison reveals trends in analysts' expectations over time.

Capture valuable insights into Roivant Sciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.

Stay up to date on Roivant Sciences analyst ratings.

Get to Know Roivant Sciences Better

Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.

Roivant Sciences: Financial Performance Dissected

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Positive Revenue Trend: Examining Roivant Sciences's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 196.03% as of 30 September, 2023, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: Roivant Sciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -820.27%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Roivant Sciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -32.74%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Roivant Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -14.48%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Roivant Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.52.

The Core of Analyst Ratings: What Every Investor Should Know

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.